Felix Baldov-Lenschen, CEO of Altus Labs, shares insights on his company's innovative AI tool for cancer drug development, called IPRO, which excels in predicting patient survival. The discussion touches on the recent turmoil in health agencies, with job cuts and a significant drug approval for a rare disease. Felix reveals how AI is reshaping oncology, enhancing treatment assessments, and improving clinical trial efficiency. The bankruptcy of 23andMe also emerges as a cautionary tale for biotech, highlighting challenges in the industry.
